ABOUT FINGER LAKES CLINICAL RESEARCH

Finger Lakes Clinical Research (FLCR) conducts adult and adolescent clinical studies with a focus on central nervous system (CNS) trials. These clinical trials encompass a broad range of illnesses including anxiety disorders, ADHD, major depression, Post-Traumatic Stress Disorder (PTSD), bipolar (manic/depressive) illness and schizophrenia. In addition, we have experience in peripheral neuropathy (pain) studies and cancer pain trials.

The Principal Investigator, Sarah D. Atkinson, MD, is a widely respected psychiatrist and researcher with over 25 years of experience in the field; she has co-authored several textbooks and journal articles. Studies are done under grants from pharmaceutical companies.

Patients are all volunteers and range in age from 6 to over 65. Trial participants typically receive a stipend for their time and travel and are not required to use health insurance nor make any kind of payment.

FLCR provides area residents important access to research studies—and our participants provide crucial help in the development of treatments that enable people to live better and healthier lives.

  • 100+ trials conducted
  • Patient and caregivers have access to Dr. Atkinson at all visits
  • Ongoing communication with referring physicians and psychologists
  • Ample onsite parking
  • Central, suburban location served by 2 bus lines
  • WiFi
  • Patient lounge
  • Patient refreshment area
  • Neuropsych testing
  • Phlebotomy lab
  • ECG Room
  • Site video monitoring recording 24 hours a day, 7 days a week
  • Monitored alarm system for fire, smoke, heat, CO and intrusion
  • Secure access-controlled laboratory, study patient file storage and drug inventory.
  • Secure temperature alarm monitored -20°c and -70°c freezers
  • Standby generator

FLCR is a 6,000-square-foot research facility designed specifically for the comfort and safety of all those participating in our clinical trials. It includes an area for patient care, a suite for trial monitors, and a 1200-square-foot secure archive storage room. The building is leased by ERG.

With recorded video surveillance and monitored electronic access, the building has optimal security. Security cameras are strategically placed around the exterior of the building and at restricted interior areas; all internal and external doors are secured by logged electronic access control, restricted by time, personnel authorization and area sensitivity as appropriate.

The onsite laboratory manages blood, urine, pregnancy and other biological testing, as well as prep and packaging of samples. It has two refrigerated, ambient centrifuges, a -20° c freezer and a -70°c freezer and an on-demand supply of dry ice. All equipment is calibrated annually to manufacturer’s standards.

The University of Rochester Strong Memorial Hospital, a tertiary trauma center, is approximately five miles from the site; it is the nearest emergency department.

Sarah D. Atkinson, MD

Sarah D. Atkinson, MD is the Director and Principal Investigator at FLCR. She has focused on clinical research since 1987 and has conducted close to one-hundred clinical trials, principally in adult and pediatric central nervous system disorders; these include: major depression, ADHD, schizophrenia, bipolar disorder and anxiety.

Dr. Atkinson is a Board-Certified psychiatrist and an elected member of The American College of Psychiatrists. She is certified in both adult and child psychiatry, and is widely published in her field, including co-authorship of two standard reference works.

Dr. Atkinson received her education at Tulane University (BS, mathematics), Princeton University (MS, mathematics) and The University of Oklahoma (MD). She completed both her residency at the University of Oklahoma and a Child Fellowship at the Menninger Clinic.

FLCR has demonstrated expertise in a range of adult and adolescent disorders and disease states; specifically it has experience in the areas listed below.

Adult and Adolescent Clinical Trials

  • Attention Deficit Hyperactivity Disorder (ADHD), Adult, Phase III
  • Attenuated Psychotic Syndrome, Adolescents and Young Adults
  • Bipolar I Disorder, manic, depressed, Phase II, III, IV
  • Depressive Disorder
  • Major Depressive Disorder (MDD), Phase II, III
  • Treatment-Resistant Depression, Phase II, III
  • Depression with Mixed Features, Phase II
  • Generalized Anxiety Disorder (GAD), Phase III, IV
  • Obsessive Compulsive Disorder (OCD), Phase II, III
  • Post-Traumatic Stress Disorder (PTSD), Phase II
  • Schizophrenia, Phase II, III
  • Schizophrenia Negative Symptoms, Phase II/III
  • Schizophrenia, Cognition, Phase II, III
  • Schizophrenia, Residual Positive Symptoms, Phase II, III
  • Schizophrenia, New Onset MRI sequential imaging, Phase III
  • Social Anxiety Disorder (SAD), Phase II

Pediatric Clinical Trials

  • ADHD, ADHD with aggression, Phase III
  • Bipolar Disorder type I Manic/Depressed, Phase III
  • Generalized Anxiety Disorder, Phase III
  • Major Depressive Disorder, Phase III, IV
  • Schizophrenia, Phase II, IIII
  • Schizophrenia, partial response to treatment, Phase III
  • Tourette’s Disorder, Phase II, III, IV

Epidemiologic

  • Depression and children with first degree relative(s) with Bipolar I
  • Children with Depressive Disorders, Anxiety Disorders
  • Natural Progression of Tardive Dyskinesia in Adults
  • Work Readiness in a normal population